Kathryn A. Bowman

Kathryn A. Bowman

Auto-generated profile, based on publicly available information

Kathryn A. Bowman

Division of Infectious Diseases, Brigham & Women’s Hospital, Boston, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Science Immunology
Verified
Journal Article
Open access
PKPaulina Kaplonek
Paulina Kaplonek
CWChuangqi Wang
Chuangqi Wang
YBYannic Bartsch
Yannic Bartsch
SFStephanie Fischinger
Stephanie Fischinger
MGMatthew J. Gorman
Matthew J. Gorman
GAGalit Alter
Galit Alter
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19.

24 April 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
LDLeela R. L. Davies
Leela R. L. Davies
CWChuangqi Wang
Chuangqi Wang
PSPia Steigler
Pia Steigler
KBKathryn A. Bowman
Kathryn A. Bowman
SFStephanie Fischinger
Stephanie Fischinger
SFSarah M. Fortune
Sarah M. Fortune
Antibody features vary with tuberculosis (TB) disease state. Whether clinical variables, such as age or sex, influence associations between Mycobacterium tuberculosis-specific antibody responses and disease state is not well explored. Here we profiled Mycobacterium tuberculosis-specific antibody responses in 140 TB-exposed South African individuals from the Adolescent Cohort Study. We identified distinct response features in individuals progressing to active TB from non-progressing, matched controls. A multivariate antibody score differentially associated with progression (SeroScore) identified progressors up to 2 years before TB diagnosis, earlier than that achieved with the RISK6 transcriptional signature of progression. We validated these antibody response features in the Grand Challenges 6–74 cohort. Both the SeroScore and RISK6 correlated better with risk of TB progression in adolescents compared with adults, and in males compared with females. This suggests that age and sex are important, underappreciated modifiers of antibody responses associated with TB progression.

16 January 2024 in mBio
Verified
Journal Article
Open access
KBKathryn A. Bowman
Kathryn A. Bowman
PKPaulina Kaplonek
Paulina Kaplonek
RMRyan McNamara
Ryan McNamara
Antibodies represent the primary correlate of immunity following most clinically approved vaccines. However, their mechanisms of action vary from pathogen to pathogen, ranging from neutralization, to opsonophagocytosis, to cytotoxicity. Antibody functions are regulated both by antigen specificity (Fab domain) and by the interaction of their Fc domain with distinct types of Fc receptors (FcRs) present in immune cells. Increasing evidence highlights the critical nature of Fc:FcR interactions in controlling pathogen spread and limiting the disease state. Moreover, variation in Fc-receptor engagement during the course of infection has been demonstrated across a range of pathogens, and this can be further influenced by prior exposure(s)/immunizations, age, pregnancy, and underlying health conditions. Fc:FcR functional variation occurs at the level of antibody isotype and subclass selection as well as post-translational modification of antibodies that shape Fc:FcR-interactions. These factors collectively support a model whereby the immune system actively harnesses and directs Fc:FcR interactions to fight disease. By defining the precise humoral mechanisms that control infections, as well as understanding how these functions can be actively tuned, it may be possible to open new paths for improving existing or novel vaccines.

2 March 2023 in EBioMedicine
Verified
Journal Article
Open access
MMMaphe Mthembu
Maphe Mthembu
KBKathryn A. Bowman
Kathryn A. Bowman
LDLeela R.L. Davies
Leela R.L. Davies
SKSharon Khuzwayo
Sharon Khuzwayo
LMLusanda Mazibuko
Lusanda Mazibuko
EWEmily B Wong
Emily B Wong
Tuberculosis (TB) is a leading infectious cause of death worldwide and treating latent TB infection (LTBI) with TB preventative therapy is a global priority. This study aimed to measure interferon gamma (IFN-γ) release assay (IGRA) positivity (the current reference standard for LTBI diagnosis) and Mtb-specific IgG antibodies in otherwise healthy adults without HIV and those living with HIV (PLWH). One-hundred and eighteen adults (65 without HIV and 53 antiretroviral-naïve PLWH), from a peri-urban setting in KwaZulu-Natal, South Africa were enrolled. IFN-γ released following stimulation with ESAT-6/CFP-10 peptides and plasma IgG antibodies specific for multiple Mtb antigens were measured using the QuantiFERON-TB Gold Plus (QFT) and customized Luminex assays, respectively. The relationships between QFT status, relative concentrations of anti-Mtb IgG, HIV-status, sex, age and CD4 count were analysed. Older age, male sex and higher CD4 count were independently associated with QFT positivity (p = 0.045, 0.05 and 0.002 respectively). There was no difference in QFT status between people with and without HIV infection (58% and 65% respectively, p = 0.06), but within CD4 count quartiles, people with HIV had higher QFT positivity than people without HIV (p = 0.008 (2nd quartile), <0.0001 (3rd quartile)). Concentrations of Mtb-specific IFN-γ were lowest, and relative concentrations of Mtb-specific IgGs were highest in PLWH in the lowest CD4 quartile. These results suggest that the QFT assay underestimates LTBI among immunosuppressed people with HIV and Mtb-specific IgG may be a useful alternative biomarker for Mtb infection. Further evaluation of how Mtb-specific antibodies can be leveraged to improve LTBI diagnosis is warranted, particularly in HIV-endemic areas. NIH, AHRI, SHIP: SA-MRC and SANTHE.

4 January 2024 in iScience
Verified
Journal Article
Open access
KBKathryn A. Bowman
Kathryn A. Bowman
CWChristine D. Wiggins
Christine D. Wiggins
EDElizabeth DeRiso
Elizabeth DeRiso
SPSteffan Paul
Steffan Paul
KSKlemen Strle
Klemen Strle
GAGalit Alter
Galit Alter
Lyme arthritis, caused by the spirochete Borrelia burgdorferi, is the most common feature of late disseminated Lyme disease in the United States. While most Lyme arthritis resolves with antibiotics, termed “antibiotic-responsive”, some individuals develop progressive synovitis despite antibiotic therapy, called “antibiotic-refractory” Lyme arthritis (LA). The primary drivers behind antibiotic-refractory arthritis remain incompletely understood. We performed a matched, cross-compartmental comparison of antibody profiles from blood and joint fluid of individuals with antibiotic-responsive (n = 11) or antibiotic-refractory LA (n = 31). While serum antibody profiles poorly discriminated responsive from refractory patients, a discrete profile of B.burgdorferi-specific antibodies in joint fluid discriminated antibiotic-responsive from refractory LA. Cross-compartmental comparison of antibody glycosylation, IgA1, and antibody-dependent complement deposition (ADCD) revealed more poorly coordinated humoral responses and increased ADCD in refractory disease. These data reveal B.burgdorferi-specific serological markers that may support early stratification and clinical management, and point to antibody-dependent complement activation as a key mechanism underlying persistent disease.

15 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
APAlyssa Pradhan
Alyssa Pradhan
BWBennett Waxse
Bennett Waxse
WMWilfredo Matias
Wilfredo Matias
SMSarah F Mercaldo
Sarah F Mercaldo
KBKathryn Bowman
Kathryn Bowman
JHJames M Hillis
James M Hillis
Objectives: Large language models (LLMs) are increasingly used in medicine, but evaluation is often on multiple choice questions and management of common conditions. Infectious diseases (ID) can present complex scenarios that require considerations beyond guideline- based responses. We assessed LLM performance in these situations including with ID- specific criteria to consider infection control or antimicrobial stewardship (AMS). Methods: We evaluated four LLMs (Claude 3.5 Sonnet, GPT-4o, GPT-o1, and a local instance of Llama 3.1 8B) in October 2024, on five complex ID vignettes. The LLM responses were each evaluated for 18 items by two board-certified ID clinicians and pairwise comparisons were performed between LLMs. Results: There was no significant difference between performance of GPT-o1, GPT-4o and Claude Sonnet on general medical criteria, and were comparable with respect to how often they provided an unsafe response (GPT-o1 30%, GPT-4o 40%, Claude 37%) and contained a critical omission (GPT-o1 27%, GPT-4o 43%, Claude 47%). Llama 3.1 8B had significantly decreased performance for most criteria. On ID-specific criteria, GPT-o1 outperformed other models and all models significantly outperformed Llama for interpreting microbiology results, AMS principles, appropriate antimicrobial spectrum and infection control considerations. Performance was poor in secondary prevention and management of risk factors. Conclusions: On complex ID scenarios, LLM responses were variable. The open-source, smaller Llama 3.1 8B model performed poorly and large, non-reasoning models varied, but more than 30% of responses containing a risk of harm or critical omission. These findings suggest caution is required when deploying these models in ID domains without specialist oversight. Summary: This evaluation of LLM responses to complex ID scenarios, demonstrates variable performance between large and small models, with more than 30% of responses containing risk of harm or critical omission. Caution is required when using models without ID-specialist oversight.